Here are five takeaways:
1. In spine surgery, the dominant biologic is bone morphogenetic protein.
2. The costliness of the process will deter the growth of the global spine biologics market, however.
3. North America dominates the global market because of developed technologies and hospitals, medical literacy and increases in the citizens’ per capita income.
4. The Asia-Pacific market will likely grow at a significant rate in the coming years because of the rising population and improving medical technology. Additionally, industry demand will increase in India and China.
5. Key companies include Alphatec Spine, DePuy Synthes, Medtronic, Stryker Corp., Smith & Nephew, Orthovita, Zimmer Biomet, K2M, NuVasive, Lattice Biologics, Arthrex, DMP Spine, Orthofix, RTI Surgical, Wright Medical Technology, Cesca Therapeutics and Precision Spine.
More articles on devices:
United Orthopedic enrolls first patient in U2 Knee System study — 4 insights
45 financial updates on 9 key orthopedic companies: Medtronic, Stryker, Zimmer Biomet & more
3 new spine, orthopedic device launches & releases — May 23, 2017
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.